STOCK TITAN
  1. Home
  2. Sec-filings
  3. CVKD
  4. [Form 4] Cadrenal Therapeutics, Inc. Insider Trading Activity

Cadrenal Therapeutics (CVKD) CEO Quang Pham sells 11,156 shares under 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Cadrenal Therapeutics, Inc. director and Chairman, CEO and Interim CFO Quang X. Pham reported open-market sales of the company’s common stock. He sold 2,127 shares at $3.00 per share and 9,029 shares at a weighted average of $3.05 per share in late June 2026.

The sales were made under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following these transactions, Pham held 105,989 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, for which he has sole voting and dispositive power.

Positive

  • None.

Negative

  • None.
Insider Pham Quang X
Role Chairman, CEO and Interim CFO
Sold 11,156 shs ($34K)
Type Security Shares Price Value
Sale Common Stock 9,029 $3.05 $28K
Sale Common Stock 2,127 $3.00 $6K
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 105,989 shares (Direct, null); Common Stock — 200,000 shares (Indirect, The PVBQ Living Trust)
Footnotes (1)
  1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 through $3.18. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.
Shares sold on June 26, 2026 9,029 shares at $3.05/share Open-market sale of common stock
Shares sold on June 25, 2026 2,127 shares at $3.00/share Open-market sale of common stock
Total shares sold 11,156 shares Net sell volume in this Form 4
Direct holdings after transactions 105,989 shares Common stock held directly post-sale
Indirect holdings via trust 200,000 shares The PVBQ Living Trust common stock
Price range of sales $3.00–$3.18 per share Multiple transactions within this range
Trading plan adoption date September 25, 2025 Rule 10b5-1 trading arrangement
Rule 10b5-1 trading arrangement financial
"shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement"
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
The PVBQ Living Trust financial
"The PVBQ Living Trust and has sole voting and dispositive power"
sole voting and dispositive power financial
"has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pham Quang X
(Last)(First)(Middle)
C/O CADRENAL THERAPEUTICS, INC.
822 A1A NORTH, SUITE 306
(Street)
PONTE VEDRA FLORIDA 32082
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
Chairman, CEO and Interim CFO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/25/2026S2,127(1)D$3115,018D
Common Stock06/26/2026S9,029(1)D$3.05(2)105,989D
Common Stock200,000IThe PVBQ Living Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares of the Issuer's common stock sold by the Reporting Person in accordance with a Rule 10b5-1 trading arrangement adopted by the Reporting Person on September 25, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.00 through $3.18. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and dispositive power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.
/s/ Quang X. Pham06/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Cadrenal Therapeutics (CVKD) report for Quang Pham?

Cadrenal Therapeutics reported that Quang X. Pham executed two open-market sales totaling 11,156 common shares. He sold 2,127 shares at $3.00 and 9,029 shares at a weighted-average price of $3.05 per share during late June 2026.

Were the CVKD insider stock sales by Quang Pham under a Rule 10b5-1 plan?

Yes. The filing states the reported Cadrenal Therapeutics share sales were made under a Rule 10b5-1 trading arrangement adopted by Quang X. Pham on September 25, 2025, indicating the transactions were pre-planned rather than opportunistic market timing.

How many Cadrenal Therapeutics (CVKD) shares does Quang Pham hold after these transactions?

After the reported sales, Quang X. Pham holds 105,989 CVKD shares directly. He also has indirect ownership of 200,000 shares through The PVBQ Living Trust, where he has sole voting and dispositive power, according to the filing footnotes.

What prices did Quang Pham receive for his Cadrenal Therapeutics (CVKD) share sales?

The filing shows he sold 2,127 shares at $3.00 per share and 9,029 shares at a weighted-average price of $3.05. The footnotes note these occurred in multiple trades ranging between $3.00 and $3.18 per share.

What role does Quang Pham hold at Cadrenal Therapeutics (CVKD)?

Quang X. Pham is identified as a director, Chairman, CEO and Interim CFO of Cadrenal Therapeutics, Inc., and is also described as a ten percent owner, indicating a significant leadership and ownership position at the company.